Inderes käyttää evästeitä tarjotakseen paremman käyttökokemuksen ja henkilökohtaisemman palvelun. Hyväksymällä evästeiden käytön voimme kehittää palvelua entistä paremmin ja pystymme tarjoamaan sinua kiinnostavaa sisältöä.
OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.
* Transition of US sales team to drive a turnaround in sales generation * No change to mid-term targets * Fair value range revised down to SEK 3.1-5.1 (3.2-5.4) Miss on sales, but opex better in Q3 Q3 marked another quarter with soft sales momentum but...
* 42% beat (less negative) on adj EBIT but miss on sales * -20% organic growth (ABGSCe -18%) * No change in outlook Q3 results OssDsign reported a mixed set of numbers in Q3 with 3% lower sales, gross margin in line, but good cost control on opex resulting...
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
Mahdollistaa yhtiöiden seuraamisen ja ilmoitusten tilaamisen
* We expect soft sales momentum for Q3e * Negative earnings revisions on lower sales * Q3'26 results due 3 November Q3'26 expectations We do not expect to see any major change in OssDsign's sales development in Q3e, compared with previous quarters during...
* Expected return to growth pushed out to Q4 * Adj. EBIT cut by 2.6%-3.6% for '26e-'28e * Fair value range revised down to SEK 3.8-6.2 (4.0-6.3) Small miss on sales, but lower opex in Q2 OssDsign reported mixed results in Q2: sales were 1% below expectations...
* 10% beat on adj EBIT but lower saIes * -16% organic growth (ABGSCe -15%) * No change in outlook, Q3 seasonally soft Q2 results OssDsign reported a mixed set of numbers in Q2 with 1% lower sales, lower gross margin, but good cost control on opex resulting...
* Sequentially flattish, but -15% organic drop in sales in Q2e * We assume a recovery in sales growth in H2'26e * Q2'26 results due 18 August Q2'26 expectations We expect sales development to have stabilised in Q2, at a similar level to Q1'26, but lower...
* Q1 in line with pre-announced numbers * Minor estimate revisions, H2'26 the key catalyst * Fair value range unchanged at SEK 4.0-6.2 Weak GM in Q1, opex offset Q1 sales confirmed the pre-announced number of SEK 36.9m (0% vs. ABGSCe) with an organic...